Kagota Satomi, Maruyama Kana, McGuire John J
Department of Pharmacology, School of Pharmacy and Pharmaceutical Sciences, Mukogawa Women's University, Nishinomiya, Hyogo 6638179, Japan.
Cardiovascular Research Group, Division of BioMedical Sciences, Faculty of Medicine, Memorial University, St. John's, Newfoundland and Labrador, Canada A1B 3V6.
Biomed Res Int. 2016;2016:3130496. doi: 10.1155/2016/3130496. Epub 2016 Feb 23.
Proteinase-activated receptor 2 (PAR2) is a cell surface receptor activated by serine proteinases or specific synthetic compounds. Interest in PAR2 as a pharmaceutical target for various diseases is increasing. Here we asked two questions relevant to endothelial dysfunction and diabetes: How is PAR2 function affected in blood vessels? What role does PAR2 have in promoting obesity, diabetes, and/or metabolic syndrome, specifically via the endothelium and adipose tissues? We conducted a systematic review of the published literature in PubMed and Scopus (July 2015; search terms: par2, par-2, f2lr1, adipose, obesity, diabetes, and metabolic syndrome). Seven studies focused on PAR2 and vascular function. The obesity, diabetes, or metabolic syndrome animal models differed amongst studies, but each reported that PAR2-mediated vasodilator actions were preserved in the face of endothelial dysfunction. The remaining studies focused on nonvascular functions and provided evidence supporting the concept that PAR2 activation promoted obesity. Key studies showed that PAR2 activation regulated cellular metabolism, and PAR2 antagonists inhibited adipose gain and metabolic dysfunction in rats. We conclude that PAR2 antagonists for treatment of obesity indeed show early promise as a therapeutic strategy; however, endothelial-specific PAR2 functions, which may offset mechanisms that produce vascular dysfunction in diabetes, warrant additional study.
蛋白酶激活受体2(PAR2)是一种由丝氨酸蛋白酶或特定合成化合物激活的细胞表面受体。将PAR2作为各种疾病的药物靶点的关注度正在不断提高。在此,我们提出了两个与内皮功能障碍和糖尿病相关的问题:PAR2在血管中的功能是如何受到影响的?PAR2在促进肥胖、糖尿病和/或代谢综合征方面,特别是通过内皮和脂肪组织发挥着什么作用?我们对PubMed和Scopus上已发表的文献进行了系统综述(2015年7月;检索词:par2、par-2、f2lr1、脂肪、肥胖、糖尿病和代谢综合征)。七项研究聚焦于PAR2与血管功能。肥胖、糖尿病或代谢综合征的动物模型在不同研究中有所差异,但每项研究均报告称,在存在内皮功能障碍的情况下,PAR2介导的血管舒张作用得以保留。其余研究聚焦于非血管功能,并提供了支持PAR2激活促进肥胖这一概念的证据。关键研究表明,PAR2激活调节细胞代谢,PAR2拮抗剂可抑制大鼠的脂肪增加和代谢功能障碍。我们得出结论,用于治疗肥胖的PAR2拮抗剂确实作为一种治疗策略展现出了早期前景;然而,内皮特异性PAR2功能可能会抵消糖尿病中产生血管功能障碍的机制,这值得进一步研究。